

REMARKS

The examiner states in the Notice of Allowability that claims numbered 1-17 are allowed. The Corrected Notice of Allowance and Fee(s) Due mailed August 13, 2004 states the total fee(s) are due November 15, 2004.

The specification was amended to more clearly set forth the continuity data for the present application.

Claim number 1 and claim number 4 are amended herein to more clearly define the invention of the present application. Claim number 12 is amended herein to correct typographical errors.

Applicant respectfully requests rejoinder of claims numbered 13, 14, 16 and 17, previously withdrawn pursuant to 37 CFR §1.142. Applicant elected, in the Response mailed February 4, 2000, the invention of Group 1: Claims 1-12 and 15, drawn to compounds in which M is $-C(R^{27})=C(R^{28})-$, and $c + d = 0$. The Examiner stated in the Office Action mailed January 19, 2000, paper number 5, page 4, line 14: "Nevertheless, in the event that one of Groups 1-8 is elected, and claims therein found allowable, the method-of-use claims will be rejoined therewith, subject to the same limitations [*In re Ochiai* (37 U.S.P.Q.2d, 1127)]", (emphasis added). Although the examiner states in the Notice of Allowability claims numbered 1-17 are allowed, claims numbered 13, 14, 16 and 17 were withdrawn from consideration in the Office Action mailed September 10, 2002, paper number 8, without subsequent record of their rejoinder. Therefore, Applicant respectfully requests rejoinder of previously withdrawn claims numbered 13, 14, 16 and 17. Also, please note the word "s[c]ystic" is misspelled in claim 17. If necessary, Applicant will submit a Supplemental Amendment to formalize the correction.

Applicant has enclosed herewith an Information Disclosure Statement pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98. It is respectfully requested that these references be considered

Attorney Docket No. 5573.210-US
Peschke et al.
Serial No. 09/356,313 Filed July 16, 1999
Express Mail Label No.: EV 246880584 US

by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein.

Applicant respectfully requests reconsideration of the claims in light of the above amendments and remarks.

The examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Applicant respectfully submits the claims are in condition for allowance and requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

A handwritten signature in cursive script, reading "Rosemarie R. Wilk-Orescan", written in dark ink. The signature is fluid and extends to the right with a long horizontal stroke.

Date: November 12, 2004

Rosemarie R. Wilk-Orescan
Registration Number 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE